Micro-dose radiation using oncolytic viruses. How oncolytic viruses kill cancer cells, and teach surviving cells to absorb small but lethal doses of radiation. Futurist Keynote Speaker and advisor on health and biotech trends to global companies

Futurist Keynote Speaker: Posts, Slides, Videos - BioTech and MedTech Keynote Speaker

More: http://www.virttu.com. How oncolytic viruses can target radiotherapy - micro-dose radiation targeted precisely to kill cancer cells. Replication of oncolytic viruses inside tumours. Pre-clinical trials. Phase I, Phase II and Phase III clinical trials on oncolytic viruses.

Why targeted cancer therapy -- a so-called "magic bullet" is so needed. How oncolytic viruses have been modified so that they cannot replicate in normal cells, but are still able to divide in a wide variety of human cancer cells. History of oncolytic viruses. Arming oncolytic viruses to carry payloads which are toxic to cancer cells

Using viruses like Seprehvir (HSV-1716) which has been developed by Virttu Biologics Ltd, adapted to carry an additional payload: extra genes which teach infected cancer cells to take up a compound containing radioactive iodine from the blood, delivering a micro-dose of radiation inside individual cancer calls. Or adding a gene which teaches cancer cells how to split a harmless pro-drug into two, inside the cell, releasing a very effective chemotherapy (alkylating agent). Targetting oncolytic viruses -- by adapting the feet of a virus to that they latch onto receptors on the surface of specific human cancer cells such as prostate (prostate antigens / PSA).

Oncolytic virus Seprehvir has passed an FDA safety review with approval for systemic administration of oncolytic viruses to children with advanced cancer. How genes work in viruses, and how genetic engineering allows us to cut and paste genes from one species into another.

Seprehvir (HSV-1716) and many other variants. Seprehvir has been shown to be highly effective against a wide range of cancers in pre-clinical studies. Seprehvir has been used in clinical trials with strong evidence of impact and almost negligible side effects - trials in glioblastoma (brain cancer), squamous cell carcinoma of head and neck and melanoma. Seprehvir is now being used in clinical trials for mesothelioma (lung cancer caused by asbestos), with others planned for hepatocellular carcinoma (live cancer) and ovarian cancer.

Use of oncolytic viruses to treat advanced malignant melanoma and mestatases -- Amgen research using an oncolytic virus developed from HSV (Herpes Simplex Virus). Problems with traditional chemotherapy -- side effects. Why Amgen bought an oncolytic viruse for $500m in cash and $500m to be paid if oncolytic trials are fully successful. Investor interest in oncolytic viruses. Oncolytic virus fund. Lessons from the history of research and development in monoclonal antibodies in cancer treatment.

Oncolytic virotherapy: Results of early Phase III Rheolysin clinical trials -- combined oncolytic virus and cancer chemotherapy. Side effects and safety profile of oncolytic viruses in clinical studies.

Video made by Patrick Dixon author of The Genetic Revolution, Chairman of Global Change Ltd, an advisor to many large pharma companies and was Chairman of Virttu Biologics Ltd which owns the oncolytic virus.

Need a world-class biotech keynote speaker? Phone Patrick Dixon now or email. Read FREE SAMPLE of The Future of Almost Everything - his latest book.

OncoVEX GM-CSF developed by BioVex in phase III for advanced melanoma, could become first approved oncolytic virus in the western world. OncoVEX GM-CSF is also in a phase 3 trial for head and neck cancer. Reolysin (owned by Oncolytics Biotech) is in phase 3 clinical trials for head and neck cancer with early results in colorectal cancer. JX-594 is owned by Jennerex and in clinical trials for hepatocellular carcinoma. JX-594 is a thymidine kinase-deleted Vaccinia virus plus GM-CSF. NTX-010 is in clinical trials for small cell lung cancer and neuroblastoma. CGTG-102 (Ad5/3-D24-GMCSF) is owned by Oncos Therapeutics. GL-ONC1 is owned by Genelux in Phase I clinicla trials. Cavatak is being developed to treat malignant melanoma. Oncorine was approved a few years ago in China for treatment of head and neck cancer - built from H101 virus.

http://www.youtube.com/watch?v=5vDVYFCF8S8

Declaration of interest: after writing this article, the author became Chairman of Virttu Biologics Ltd.  The company was subsequently bought by Sorrento Therapeutics Inc in 2017.

< Prev		Next >